Compare Sanofi SA (SNY) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Valero Energy Corporation — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Valero Energy Corporation trades at $331.25 (market cap $93.27B). The key difference: Sanofi SA and Valero Energy Corporation are close in size by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | VLO | |
|---|---|---|
Market Cap | $104.30B | $93.27B |
Sector | Health | Energy |
52-Week High | $52.34 | $323.92 |
52-Week Low | $41.33 | $133.38 |
Enterprise Value | $124.19B | $96.74B |
Dividend Yield | 5.55% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Valero Energy (VLO) trades at $329.99, up 4.78% on the day, reflecting strong momentum after recent earnings beats. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals indicate robust profitability with a 29.31% ROE and a P/E of 13.51. Recent news highlights refining strength and geopolitical factors benefiting the sector.
Outlook remains positive with analyst consensus favoring a Buy rating and a $324.27 price target. Key risks include volatile oil prices and refining margin pressures, but disciplined capital allocation and renewable diesel growth offer upside potential for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
